TP 2
Alternative Names: TP-2Latest Information Update: 20 Jul 2022
At a glance
- Originator Zhiyi Biotechnology
- Class Anti-inflammatories; Bacterial polysaccharides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ulcerative colitis
Most Recent Events
- 11 Jul 2022 Preclinical trials in Ulcerative colitis in China (PO) (Zhiyi Biotechnology pipeline, July 2022)